Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript

Jan 06, 2022 / 04:00PM GMT
Release Date Price: $85.38 (-2.11%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning, everyone. Thank you for joining us at the Goldman Sachs CEOs Unscripted Conference 2022. We're really pleased to have Jean-Jacques Bienaime, Chairman and CEO of BioMarin, J.J., thank you for joining us this morning.

2022 looks to be an inflection year for BioMarin with the launch of recently approved VOXZOGO and potentially submission and approval for ROCTAVIAN, 2 blockbuster drugs. As you look to this year, where are you focused? And is there anything that you are doing differently that is unique to these 2 products?

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Thank you, Salveen. So as you highlighted, indeed, we believe that 2022 will be a transformational year for BioMarin. Our most recently approved product, VOXZOGO, for the treatment of children with achondroplasia is expected to drive us to sustainable GAAP profitability this year. As the only therapeutic treatment available for patients with achondroplasia, this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot